Rhonda Farnum Sells 13,314 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $16.58 on Friday. The company has a market cap of $854.70 million, a PE ratio of 7.54 and a beta of 0.17. The company has a fifty day moving average price of $16.50 and a two-hundred day moving average price of $17.37. Theravance Biopharma, Inc. has a 12 month low of $10.44 and a 12 month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The business had revenue of $17.70 million for the quarter. Equities research analysts anticipate that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. TD Cowen lifted their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, March 23rd. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. HC Wainwright raised their price target on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Two analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $21.40.

Institutional Trading of Theravance Biopharma

A number of large investors have recently modified their holdings of the company. Quarry LP acquired a new position in Theravance Biopharma during the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.